Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Sheila Annie Peters

https://doi.org/10.1007/BF00265978.

      6 Chu, V. et al. (2009). In vitro and in vivo induction of cytochrome P450: A survey of the current practices and recommendations: A Pharmaceutical Research and Manufacturers of America perspective. Drug Metabolism and Disposition 37 (7): 1339–1354. https://doi.org/10.1124/dmd.109.027029.

      7 Dunne, J. et al. (2011) ‘Extrapolation of adult data and other data in pediatric drug‐development programs’, Pediatrics, 128(5), p. e1242. doi: 10.1542/peds.2010‐3487.

      8 El‐Sankary, W. et al. (2001). Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metabolism and Disposition 29 (11): 1499–1504.

      9 EMA (2013). Guideline on the investigation of drug interactions. In: London. https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐investigation‐drug‐interactions‐revision‐1_en.pdf.

      10 Fahmi, O.A. and Ripp, S.L. (2010). Evaluation of models for predicting drugdrug interactions due to induction. Expert Opinion on Drug Metabolism and Toxicology 6 (11): 1399–1416. https://doi.org/10.1517/17425255.2010.516251.

      11 Franklin, M.R. (1991). Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods in Enzymology 206 (C): 559–573. https://doi.org/10.1016/0076‐6879(91)06126‐N.

      12 Galetin, A. et al. (2006). Prediction of time‐dependent CYP3A4 drug‐drug interactions: Impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metabolism and Disposition 34 (1): 166–175. https://doi.org/10.1124/dmd.105.006874.

      13 Grime, K.H. et al. (2009). Mechanism‐based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug‐drug interaction prediction methods. European Journal of Pharmaceutical Sciences 36 (2–3): 175–191. https://doi.org/10.1016/j.ejps.2008.10.002.

      14 Grimm, S.W. et al. (2009). The conduct of in vitro studies to address time‐dependent inhibition of drug‐metabolizing enzymes: A perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metabolism and Disposition 37 (7): 1355–1370. https://doi.org/10.1124/dmd.109.026716.

      15 Harper, T.W. and Brassil, P.J. (2008). Reaction phenotyping: Current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS Journal 10 (1): 200–207. https://doi.org/10.1208/s12248‐008‐9019‐6.

      16 Ho, R.H. and Kim, R.B. (2005). Transporters and drug therapy: Implications for drug disposition and disease. Clinical Pharmacology and Therapeutics 78 (3): 260–277. https://doi.org/10.1016/j.clpt.2005.05.011.

      17 Hollenberg, P.F., Kent, U.M., and Bumpus, N.N. (2008). Mechanism‐based inactivation of human cytochromes P450s: Experimental characterization, reactive intermediates, and clinical implications. Chemical Research in Toxicology: 189–205. https://doi.org/10.1021/tx7002504.

      18 Inotsume, N. et al. (1990). The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. Journal of Clinical Pharmacology 30 (1): 50–56. https://doi.org/10.1002/j.1552‐4604.1990.tb03438.x.

      19 Ivanyuk, A. et al. (2017). Renal drug transporters and drug interactions. Clinical Pharmacokinetics: 825–892. https://doi.org/10.1007/s40262‐017‐0506‐8.

      20 Jing, X. et al. (2020) ‘Update on therapeutic protein–drug interaction: Information in labeling’, Clinical Pharmacokinetics. 59(1), pp. 25–36. doi: 10.1007/s40262‐019‐00810‐z.

      21 Jones, N.S. et al. (2020). Complex DDI by fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI. Clinical Pharmacology and Therapeutics 107 (1): 269–277. https://doi.org/10.1002/cpt.1599.

      22 Kalgutkar, A.S., Obach, R.S., and Maurer, T.S. (2007). Mechanism‐based inactivation of cytochrome P450 enzymes: Chemical mechanisms, structure‐activity relationships and relationship to clinical drug‐drug interactions and idiosyncratic adverse drug reactions. Current Drug Metabolism 8 (5): 407–447. https://doi.org/10.2174/138920007780866807.

      23 Kanebratt, K.P. and Andersson, T.B. (2008). HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metabolism and Disposition 36 (1): 137–145. https://doi.org/10.1124/dmd.107.017418.

      24 Kato, M. et al. (2005). The quantitative prediction of in vivo enzyme‐induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metabolism and Pharmacokinetics 20 (4): 236–243. https://doi.org/10.2133/dmpk.20.236.

      25 Kenny, J. R., Ramsden D., Buckley, D. B. et al. (2018). Considerations from the Innovation and Quality Induction Working Group in Response to Drug‐Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance. Drug Metabolism and Disposition. 46 (9): 1285–1303. https://doi.org/10.1124/dmd.118.081927.

      26 Kirch, W. et al. (1987). Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clinical Pharmacokinetics 13 (2): 110–117. https://doi.org/10.2165/00003088‐198713020‐00003.

      27 Lau, Y.Y. et al. (2007). Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clinical Pharmacology and Therapeutics 81 (2): 194–204. https://doi.org/10.1038/sj.clpt.6100038.

      28 LeCluyse, E. et al. (2000). Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. Journal of Biochemical and Molecular Toxicology 14 (4): 177–188. https://doi.org/10.1002/(SICI)1099‐0461(2000)14:4<177::AID‐JBT1>3.0.CO;2‐4.

      29 Luo, G. et al. (2005). CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Current Drug Metabolism 5 (6): 483–505. https://doi.org/10.2174/1389200043335397.

      30 MHLW (Ministry of Health, Labour and Welfare). 2018. Guideline on drug interaction for drug development and appropriate provision of information (final draft), MHLW, Tokyo, Japan. https://www.pmda.go.jp/files/000228122.pdf.

      31 Mills, J.B. et al. (2004). Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. Journal of Pharmacology and Experimental Therapeutics 309 (1): 303–309. https://doi.org/10.1124/jpet.103.061713.

      32 Obach, R.S., Walsky, R.L., and Venkatakrishnan, K. (2007). Mechanism‐based inactivation of human cytochrome P450 enzymes and the prediction